Core Viewpoint - The company reported a revenue of 41.188 billion yuan for the first half of 2025, reflecting a year-on-year growth of 3.54% [1] - The net profit attributable to shareholders reached 282 million yuan, marking an 18.56% increase compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 277 million yuan, showing a significant growth of 26.68% year-on-year [1] - The basic earnings per share stood at 0.16 yuan [1] Financial Performance - Revenue for the reporting period was 41.188 billion yuan, up 3.54% year-on-year [1] - Net profit attributable to shareholders was 282 million yuan, an increase of 18.56% [1] - Net profit after deducting non-recurring items was 277 million yuan, reflecting a growth of 26.68% [1] - Basic earnings per share were reported at 0.16 yuan [1]
重药控股(000950.SZ)发布上半年业绩,归母净利润2.82亿元,同比增长18.56%